Skip to main content

Table 3 Clinical performance of Lumipulse assays in a validation cohort

From: Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease

 

Controls (n = 10)

AD (n = 20)

Total (n = 30)

Gender (M/F)

3/7

9/11

12/18

Age (years)

58.2 ± 10.7

67.2 ± 6.2

64.2 ± 9.7

Correctly classified

 Lumipulse

   

  Aβ42

10 (100%)

15 (75%)

25 (83%)

  t-Tau

10 (100%)

18 (90%)

28 (93%)

  p-Tau

10 (100%)

17 (85%)

27 (90%)

  Aβ42/Aβ40

10 (100%)

19 (95%)

29 (97%)

  Aβ42/t-Tau

10 (100%)

19 (95%)

29 (97%)

  Aβ42/p-Tau

10 (100%)

19 (95%)

29 (97%)

  1. Data are expressed as mean ± SD (age), as number of males (M) and females (F), and as the number (%) of correctly classified samples according to the previously determined cut-offs for Lumipulse assays